Assessment of Tubal Occlusion During Minimally Invasive Myomectomy

Launched by MEDSTAR HEALTH RESEARCH INSTITUTE · May 16, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how fibroids, which are non-cancerous growths in the uterus, affect the fallopian tubes and how their removal through surgery impacts these tubes. The study will use a safe procedure called chromopertubation, where a special dye is injected into the uterus to see if it flows through the fallopian tubes. This helps doctors check if the tubes are open or blocked, which is important for natural pregnancy. The trial aims to find out if having fibroids affects whether the tubes are blocked before surgery and if their condition changes after the fibroids are removed.

To participate in this trial, women who are scheduled for minimally invasive surgery to remove fibroids may be eligible, provided they don’t have certain conditions like absent fallopian tubes or a known allergy to the dye used in the procedure. During the surgery, chromopertubation will be done at the start and end, taking about 10 minutes in total. The results will help improve our understanding of how fibroids and their removal might influence the fallopian tubes, which could be valuable information for women looking to conceive in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Patients undergoing minimally invasive laparoscopic or robotic-assisted uterine-preserving gynecologic surgery for removal of uterine fibroids (myomectomy) by a minimally invasive gynecologic surgeon at MedStar.
• Exclusion Criteria:
• • Patients with both fallopian tubes absent
• • Patients in whom it is not possible to place a uterine manipulator or catheter
• • Patient with known tubal disease or occlusion, or patients who have undergone prior tubal surgery
• • Patients with allergy to methylene blue dye or G6PD deficiency
• • Patients with positive pregnancy test on day of surgery